Rezolute, Inc. is downgraded to a Sell after its phase 3 sunRIZE trial for congenital hyperinsulinism failed. Learn more ...
Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...
In the original version of this article, the second figure contained an error. The image has been updated. It’s important for engineers to have a good, working ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback